Table 1.
Selected studies of postoperative stereotactic radiosurgery (SRS) to surgical bed
| References | Pts (No) | Date | Interval between surgery/SRS | SRS modality | Median SRS dose (Gy) | PTV (cc) | GTV-to-PTV margins | Median follow-up (months) |
|---|---|---|---|---|---|---|---|---|
| Jensen et al. [10] | 106 | 2001–2009 | 3.5 w | GK | 17 (11–23) | 12.6 (1.2–74.0) | 1 mm | NR |
| Rwigema et al. [11] | 77 | 2005–2010 | 3–4 w | CK | 12–27 in 1–3 fr (SRS 70%) | 7.6 (0.5–59) | 1 mm | 13.8 |
| Prabhu et al. [12] | 62 | 2007–2010 | 4.5 w | LINAC | 18 | 13.9 (1.6–80) | 0–2 mm; > 1 mm (95%) | 12.4 |
| Robbins et al. [13] | 85 | 2000–2011 | within 8 w | LINAC | 16 | 13.95 | 2–3 mm | 11.2 |
| Luther et al. [14] | 120 | 2002–2012 | 4 w | GK | 16 | 8 | 2–3 mm | 12.6 |
| Brennan et al. [15] | 49 | 2208–2009 | 4 w (2–8) | LINAC | 15–22 | ≥ 3 cm, 18 < 3 cm, 32 | 2 mm | 12 |
| Iorio-Morin et al. [16] | 110 | 2004–2013 | > 3w (60pts), < 3w (53pts) | GK | 18 | 12 (0.6–43) | 1 mm | 10 |
| Ojerholm et al. [17] | 91 | 2007–2013 | 6 w | GK | 16 | 9.2 | 0 mm | 9.8 |
| Abel et al. [18] | 85 | 2003–2013 | 3–6 w | GK | 17.3 (14–20) | 12 (0.3–83) | 0 mm | 16.4 |
| Eaton et al. [19] | 75 | 2007–2014 | NR | LINAC | SRS 15 (39 pts) HSRT 24–30/3–5 fr (36 pts) | SRS 20.5 HSRT 37.7 | 1.5–2 mm | 15 |
| Strauss et al. [20] | 100 | 2005–2013 | 4 w | LINAC | 20 | 4 ± 3.1 (mean) | 0 mm | 16.3 (mean) |
| Johnson et al. [21] | 112 | 2006–2013 | 2–4 w | GK | 16 | 9.85 (0.9–41.1) | 0 mm | 9 |
| Rava et al. [22] | 87 | 2002–2010 | 4 w | GK | 18 | 13.4 (3–40.8) | 1–2 mm | 7.1 |
| Brown et al. [7] | 194 | 2011–2015 | Within 4 w | LINAC/ GK/CK | SRS (12–18); WBRT (37.5/15) | NR | 2 mm | 11.1 |
| Mahajan et al. [24] | 128 | 2009–2016 | Within 4 w | GK | 16 (12–18) | NR | 1 mm | 11.1 |
| Bachmann et al. [23] | 75 | 2010–2015 | NR | LINAC | SRS 18 HSRT 40/10fr | SRS 8.4; HSRT 22.6 | 1 mm | 11.2 |
| References | 1-Year LC (%) | 1-Year DP (%) | 1-Year OS (%) | BED Gy10 (Tumor) | BED Gy2 (normal brain) | LMD (%) | Symptomatic RN (%) |
|---|---|---|---|---|---|---|---|
| Jensen et al. [10] | 80.3 | 64.6 | 46.8 | 45.9 (23.1–75.9) | 161.5 (71.5–287.5) | 7 | 2.7 |
| Rwigema et al. [11] | 76 | 46 | 62.5 | SRS 37.5 HSRT 51.3 | SRS 127.5 HSRT 148.5 | 1.3 | 3 |
| Prabhu et al. [12] | 78 | 51 | 70 | 50.4 | 180 | NR | 8 at 1 year |
| Robbins et al. [13] | 81.4 | 58.1 | 51.5 | 41.6 | 144 | NR | 8 |
| Luther et al. [14] | 87 | 40 | 63 | 41.6 | 144 | NR | 7.5 |
| Brennan et al. [15] | 78 | 44 | 50 | 37.5–70.4 | 127.5–264 | NR | 17.5 |
| Iorio-Morin et al. [16] | < 3w 87 > 3w 61 | 54 | 63 | 50.4 | 180 | 11 | 22 |
| Ojerholm et al. [17] | 81 | 27 | 45 | 41.6 | 144 | NR | 7 |
| Abel et al. [18] | 87 | 52 | 65 | 47.2 (33.6–60) | 166.9 (112–220) | NR | 8 |
| Eaton et al. [19] | SRS 27.2 HSRT 25.6 | 52 | SRS 41.1 HSRT 54.9 | SRS 37.5 HSRT 43.2–48 | SRS 127.5 HSRT 120–126 | NR | SRS 6.8 HSRT 16.4 |
| Strauss et al. [20] | 84 | 42 | 63.5 | 60 | 220 | 9.8 | 5 |
| Johnson et al. [21] | 84.4 | 50 | 12.9 | 41.6 | 144 | 16.9 at 1 year | NR |
| Rava et al. [22] | 82 | 44 | 54 | 50.4 | 180 | NR | 10.3 |
| Brown et al. [7] | SRS 60.5 WBRT 80·6 (p = 0.00068) | SRS 35 WBRT 11 (p = 0.0004) | SRS 50 WBRT 48 | SRS 26.4–50.4 WBRT 46.8 | SRS 84–180 WBRT 84.4 | SRS 7.2 WBRT 6.4 | 4 (all after SRS) |
| Mahajan et al. [24] | SRS 57 OBS 28 (p = 0.0015) | SRS 58 OBS 67 | SRS 65 OBS 63 | 41.6 26.4–50.4 | 144 84–180 | SRS 28 OBS 16 | NR |
| Bachmann et al. [23] | 72 | 40 | 64 | SRS 50.4 HSRT 56 | SRS 180 HSRT 120 | NR | 22 |
LINAC, linear accelerator; GK, Gamma Knife; CK, CyberKnife; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy; HSRT, hypofractionated stereotactic radiation therapy; OBS, observation; p, prospective; BED Gy10, biological equivalent dose with an α/β ratio of 10 Gy; BED Gy2, biological equivalent dose with an α/β ratio of 2 Gy; w, weeks; LC, local control; DP, dostant progression; OS, overall survival; NR, not reported